Search
Pravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigational[L6142] Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. … Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991.
Products: PRAVASTATIN 1A PHARMA 10MG, PRAVASTATIN 1A PHARMA 20MGQuizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigationalcytarabine consolidation, followed by a maintenance monotherapy resulted in a 22% reduction in the risk of death. … [A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo.
Meloxicam
go.drugbank.com/drugs/DB00814ApprovedInvestigationalVet approvedIt is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.[A190198,A190201] … [A190189] With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations.
Mixtures: OCAM PROTECT® 7.5 TABLETAS DE LIBERACIÓN RETARDADA, OCAM PROTECT ® 15 MG TABLETAS DE LIBERACION RETARDADAProducts: MELOXICAM 1A PHARMA 15MG, MELOXICAM 1A PHARMA 7.5MGSilicon
go.drugbank.com/drugs/DB12982ApprovedSilicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
Mixtures: C & D, Active Calcium Plus Magnesium, Vitamin D and SiliconValine
go.drugbank.com/drugs/DB00161ApprovedInvestigationalNutraceuticalValine is a branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.
Mixtures: SOLUCION DP-AMINE, TRAVASOL PLUS 15% LIBRE DE BISULFITORifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawn[L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801] … Product which allowed it to have a status a priority review.
Ketamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedKetamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. … It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332]
Synonyms: DL-ketamineFluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalFluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. … Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients.
NADH
go.drugbank.com/drugs/DB00157ApprovedNutraceuticalIt forms NADP with the addition of a phosphate group to the 2' position of the adenosyl nucleotide through an ester linkage. (Dorland, 27th ed) … NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
Mixtures: BumP DHA, BumP DHAPimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigationalIn fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … [L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous